Pacli (IV Infusion 6 mg/m 300 mg vial)

Ovarian Carcinoma: Pacli is indicated as first line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first line therapy, Pacli is indicated in combination with cisplatin. Breast Carcinoma: Pacli is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. Pacli is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracline unless clinically contraindicated. Pacli is indicated for the first-line therapy of advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracline therapy is suitable or in combination with trastuzumab in patients who overexpress HER2 at a 2+ or 3+ level as determined by immuno-histochemistry. Gemcitabine, in combination of Pacli, is indicated in the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. Pacli is indicated for the treatment of metastatic cancer of the breast, in combination with trastuzumab, in patients who have tumors that over-express HER2 and who have not received previous chemotherapy for their metastatic disease. Non-Small Cell Lung Carcinoma: Pacli, in combination with cisplatin, is indicated for the first line treatment of non-small cell lung cancerin patients who are not candidates for potential curative surgery and/or radiation therapy. Kaposi's Sarcoma: Pacli is indicated for the second line treatment of AIDS related Kaposi's Sarcoma. Gastric Carcinoma: Pacli is indicated for the treatment of Gastric Carcinoma. * রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'

Add to cart